Elicio Therapeutics, Inc. — Director's Dealing 2021

Mar 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Angion Biomedica Corp. (ANG)
CIK: 0001601485
Period of Report: 2021-03-08

Reporting Person: Nissenson Allen (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-08	Stock Option (Right to Buy)	$15.01	A	15000	Acquired	2031-03-07	Common Stock (15000)	Direct

Footnotes

F1: To vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.